Mycenax Biotech Competitors and Similar CompaniesClear all
Mycenax Biotech's competitors and similar companies include TaiGen Biopharmaceuticals Holdings, JHL Biotech, Medigen Vaccine Biologics and Taiwan Liposome.
 Mycenax Biotech Mycenax Biotech (永昕生物醫藥股份有限公司) is a company that provides biopharmaceutical development services. |  TaiGen Biopharmaceuticals Holdings TaiGen Biopharmaceuticals Holdings (太景醫藥研發控股股份有限公司) is a company that focuses on the development of therapeutics for diseases such as cancer, infections, and diabetic complications. |  Medigen Vaccine Biologics Medigen Vaccine Biologics (高端疫苗生物製劑股份有限公司) is a company developing vaccines and biosimilars to prevent regional infectious diseases. |  Taiwan Liposome Taiwan Liposome is a pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). | ||
Founding Date | Founding Date 2001 | Founding Date 2005 | Founding Date 2012 | Founding Date 2012 | Founding Date 1997 |
Type | Type Public | Type Public | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations Zhunan, TW HQ Taipei, TW Zhunan, TW | Locations Taipei, TW HQ | Locations TW HQ | Locations TW HQ | Locations Taipei, TW HQ 港区, JP Leiden, NL South San Francisco, US |
Employees | Employees 387 | Employees 498% decrease | Employees 64 | Employees 103 | Employees 1652% decrease |
Financial | |||||
Revenue (est.) | Revenue (est.) NT$740.2m (FY, 2025) | Revenue (est.) NT$259.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) NT$605.6m (FY, 2024) | Revenue (est.) NT$101.9m (FY, 2020) |
Cost of goods | Cost of goods NT$637.3m (FY, 2025) | Cost of goods NT$18.2m (FY, 2025) | Cost of goods N/A | Cost of goods NT$72.8m (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit NT$114.2m (FY, 2025) | Gross profit NT$242.8m (FY, 2025) | Gross profit N/A | Gross profit NT$532.9m (FY, 2024) | Gross profit NT$129.8m (FY, 2020) |
Net income | Net income (NT$448.6m) (FY, 2025) | Net income NT$45.2m (FY, 2025) | Net income N/A | Net income (NT$80.5m) (FY, 2024) | Net income (NT$983.3m) (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 75m | Total funding raised $ 266.6m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
TaiGen Biopharmaceuticals Holdings
HQ
Taipei, TW
Employees
49↓ 8% decrease
TaiGen Biopharmaceuticals Holdings (太景醫藥研發控股股份有限公司) is a company that focuses on the development of therapeutics for diseases such as cancer, infections, and diabetic complications.
View company
JHL Biotech
HQ
TW
Employees
64
JHL Biotech is a biopharmaceutical company that develops biosimilars.
View companyMedigen Vaccine Biologics
HQ
TW
Employees
103
Medigen Vaccine Biologics (高端疫苗生物製劑股份有限公司) is a company developing vaccines and biosimilars to prevent regional infectious diseases.
View companyTaiwan Liposome
HQ
Taipei, TW
Employees
165↓ 2% decrease
Taiwan Liposome is a pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs).
View company